Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

International Stem Cell (ISCO) Equity Average (2016 - 2025)

International Stem Cell (ISCO) has disclosed Equity Average for 15 consecutive years, with -$3.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average rose 4.78% to -$3.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$3.8 million, a 4.78% increase, with the full-year FY2024 number at -$4.1 million, up 6.78% from a year prior.
  • Equity Average was -$3.8 million for Q3 2025 at International Stem Cell, up from -$4.0 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of -$3.8 million in Q3 2025 to a low of -$4.6 million in Q4 2022.
  • A 5-year average of -$4.2 million and a median of -$4.2 million in 2024 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: tumbled 57.58% in 2021, then grew 15.05% in 2023.
  • International Stem Cell's Equity Average stood at -$4.5 million in 2021, then decreased by 2.54% to -$4.6 million in 2022, then rose by 12.28% to -$4.0 million in 2023, then grew by 0.93% to -$4.0 million in 2024, then grew by 3.75% to -$3.8 million in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Equity Average are -$3.8 million (Q3 2025), -$4.0 million (Q2 2025), and -$4.0 million (Q1 2025).